Download PDF
Thromb Haemost 1967; 18(03/04): 439-446
DOI: 10.1055/s-0038-1655053
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

On the Action Mechanism of Some Fibrinolysis Inhibitors

L Donner
1   Second Medical Department Charles University, Prague, Czechoslovakia (Head: Professor F. Herles, M. D., D. Sc.)
,
J Housková
1   Second Medical Department Charles University, Prague, Czechoslovakia (Head: Professor F. Herles, M. D., D. Sc.)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

1. Both p-aminomethylcyclohexanecarboxylic acid (AMCA) and p-aminomethylbenzoic acid (PAMBA) exhibit a significant inhibiting activity on the fibrinolysis. The inhibition conldbe observed already at concentrations as low as 10-4 M. The inhibition was higher in a system activated by urokinase than in a system activated by streptokinase. By comparing the same concentrations the greatest inhibitory activity was observed in AMCA, a lesser one in PAMBA, and the least one in EACA.

2. AMCA exhibited mostly an antiactivator effect; the inhibition of pi asm in was very weak.

3. Intravenous injections of either AMCA, in recommended therapeutic doses of 15-20 mg/kg body weight, or PAMBA, in recommended therapeutic doses of 1.5 mg/kg body weight, exhibited an inhibitive effect on the fibrinolysis in vivo. Their effects set on, on the average, inside 30-60 min, and lasted 2-6 hrs. Great individual variations were found. AMCA had the highest inhibitory effect.

4. AMCA inhibits not only the blood activator but also the tissue activator. AMCA possesses, apart from the antifibrinolytic and antifibrinogenolytic activity, also a significant antitryptic activity.

 

  • References

  • 1 Andersson L, Nilson I. M. Fibrinolytic Activity in Man During Surgery. Thrombos. Diathes. haemorrh. (Stuttg). 07: 391 1962;
    PubMedGoogle Scholar
  • 2 Andersson L, Nilson I. M, Niléhn J. E, Hedner E, Grandstrand B, Melander B. Experimental and Clinical Studies on AMCA, the Antifibrinolytically Active Isomer of p-Aminomethyl Cyclohexane Carboxylic Acid. Scand. H. Haem. 02: 230 1965;
    PubMedGoogle Scholar
  • 3 Astrup T. N, Alkjaersig N. Classification of Proteolytic Enzymes by Means of their Inhibitors. Nature. 169: 314 1952;
    CrossrefPubMedGoogle Scholar
  • 4 Astrujp T, Albrechtsen V. K. Estimation of the Plasminogen Activator and the Trypsin Inhibitor in Animal and Human Tissues. Scand. J. clin. Inv. 09: 233 1957;
    PubMedGoogle Scholar
  • 5 Astrup T, Alkjaersig N. Estimation of Proteolytic Enzymes by Means of their Fibrinolytic Activity. Arch. Bioch. 37: 99 1952;
    CrossrefPubMedGoogle Scholar
  • 6 Beck E, Schmutzler R, Duckert F. Inhibition of Fibrinolysis and Fibrinogenolysis in Man. Comparison of e-Aminocaproic Acid and Kallikrein Inhibitor. Thrombos. Diathes. haemorrh. (Stuttg). 10: 106 1963;
    PubMedGoogle Scholar
  • 7 Čepelâk V, Horâkovâ Z, Padr Z. Protease Inhibitor from Ground and Skin. Nature (Lond). 198: 295 1963;
    PubMedGoogle Scholar
  • 8 Donner L, Krcilek A. Zmëny fibrinolysy a hemokoagulace pri trombolytické lécbë. Cas. Lék. ces. 104: 641 1965;
    PubMedGoogle Scholar
  • 9 Dubber A. H, McNicol G. P, Douglas A. S. Cyklohexane Carboxylic Acid (AMCA) a New Synthetic fibrinolytic Inhibitor. Brit. J. Haem. 11: 237 1965;
    CrossrefPubMedGoogle Scholar
  • 10 Fischer M. Zur Wirkung eines neuen synthetischen Inhibitors des fibrinolytischen Systems. AB Kabi Bericht. No. 377, 1965
    PubMedGoogle Scholar
  • 11 Fischer M. Vergleichende Untersuchungen der Fibrinolyseninhibitoren AMCA, e-ACA und PAMBA. Wien. Z. inn. Med. 47: 143 1966;
    PubMedGoogle Scholar
  • 12 Forell M. M, Dobovicnik W. Untersuchungen über die Hemmfähigkeit des Blutes gegenüber Trypsin und deren Beeinflussung durch die intravenöse Verabreichung des Kallikrein -und Trypsin-Drüseninaktivator. Blut. 07: 136 1961;
    CrossrefPubMedGoogle Scholar
  • 13 Hartert H. Die Thrombelastographie. Z. exp. Med. 117: 189 1951;
    CrossrefPubMedGoogle Scholar
  • 14 Introzzi P. Die Inhibitoren der Fibrinolyse. 8. Cong. Eur. Soc. Hemat. 1961; 450.
    PubMedGoogle Scholar
  • 15 Koutský J, Hladovec J, Padovec J, Mansfeld W. Über die antifibrinolytische Wirkung des aus dem Pankreas sublingual applizierten Inhibitors. Gynek. 148: 412 1959;
    PubMedGoogle Scholar
  • 16 Kraut N, Frey E. K, Werle E. Über die Inaktivierung des Kallikreins. Z. physiol. Chem. 192: 1 1930;
    CrossrefPubMedGoogle Scholar
  • 17 Lohmann K, Markwardt F, Landmann H. Über neue Hemmstoffe der Fibrinolyse. Naturwissenschaften. 50: 502 1963;
    PubMedGoogle Scholar
  • 18 Markwardt F, Klöcking H. P, Landsmann H. Vergleichende Untersuchungen über Antifibrinolytika. Thrombos. Diathes. haemorrh. (Stuttg). 15: 562 1966;
    PubMedGoogle Scholar
  • 19 Meiander B, Gliniecki G, Grandstrand B, Hansfoff G. The Antifibrinolytically Active Isomer of AMCHA. Abstracts G 68 Xth Congress of the International Society of Haematology..
    PubMedGoogle Scholar
  • 20 Nilsson I. M, Björkman S. E, Andersson L. Clinical Experiences with e-Aminocaproic Acid as an Antifibrinolytic Agent. Acta med. scand. 170: 487 1961;
    PubMedGoogle Scholar
  • 21 Okamoto S, Okamoto U. AMCHA. A New Potent Inhibitor of the Fibrinolysis. Keio J. Med. 11: 105 1962;
    CrossrefPubMedGoogle Scholar
  • 22 Schmutzler R, Fürstenberg H. Fibrinolyse und Blutverlust nach Prostata Operationen und deren Beeinflußbarkeit durch Antifibrinolytica. Dtsch. med. Wschr. 91: 297 1966;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Schmutzler R, Beck E. Die Wirkung von e-Aminokapronsäure und Trasylol auf die Fibrinolyse. Schweiz, med. Wschr. 92: 1368 1962;
    PubMedGoogle Scholar
  • 24 Soulier J. P, Prou-Wartelle O, Darmout J. Etude de divers inhibitors d’enzymes protéolyti- ques sur la coagulation et la fibrinolyse. Rev. Hémat. 15: 431 1960;
    PubMedGoogle Scholar
  • 25 Vogel G. Klinische Erfahrungen mit p-Aminomethylbenzolsäure. Z. inn. Med. 21: 57 1966;
    PubMedGoogle Scholar
  • 26 Weiss M, Yver J, Samama M, Dubort G. h. Effects dissociés d’un nouvel antifibrinolytique injecté “in vivo” sur les epreuves “in vitro” de fibrinolyse. Prese méd. 71: 1879 1963;
    PubMedGoogle Scholar